Aixa Soyano

1.5k total citations · 1 hit paper
30 papers, 1.1k citations indexed

About

Aixa Soyano is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Aixa Soyano has authored 30 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 6 papers in Immunology. Recurrent topics in Aixa Soyano's work include Lung Cancer Research Studies (13 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Brain Metastases and Treatment (8 papers). Aixa Soyano is often cited by papers focused on Lung Cancer Research Studies (13 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Brain Metastases and Treatment (8 papers). Aixa Soyano collaborates with scholars based in United States, Spain and France. Aixa Soyano's co-authors include Yanyan Lou, Bhagirathbhai Dholaria, Keith L. Knutson, Julian A. Marin‐Acevedo, Saranya Chumsri, Rami Manochakian, David O. Hodge, Yan Luo, Alex A. Adjei and Nancy N. Diehl and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Aixa Soyano

30 papers receiving 1.0k citations

Hit Papers

Next generation of immune checkpoint therapy in cancer: n... 2018 2026 2020 2023 2018 200 400 600

Peers

Aixa Soyano
Nana-Ama A.S. Anang United States
Eileen E. Parkes United Kingdom
Jason B. Muhitch United States
Justin D. Saco United States
Aixa Soyano
Citations per year, relative to Aixa Soyano Aixa Soyano (= 1×) peers Pushpamali De Silva

Countries citing papers authored by Aixa Soyano

Since Specialization
Citations

This map shows the geographic impact of Aixa Soyano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aixa Soyano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aixa Soyano more than expected).

Fields of papers citing papers by Aixa Soyano

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aixa Soyano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aixa Soyano. The network helps show where Aixa Soyano may publish in the future.

Co-authorship network of co-authors of Aixa Soyano

This figure shows the co-authorship network connecting the top 25 collaborators of Aixa Soyano. A scholar is included among the top collaborators of Aixa Soyano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aixa Soyano. Aixa Soyano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aldrich, Amy L., Hyo S. Han, Aixa Soyano, et al.. (2025). A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer. npj Breast Cancer. 11(1). 29–29. 1 indexed citations
2.
Ahmed, Kamran A., Youngchul Kim, John A. Arrington, et al.. (2025). Phase II trial of brain MRI surveillance in stage IV breast cancer. Neuro-Oncology. 27(6). 1550–1558. 1 indexed citations
3.
Han, Hyo S., Amy L. Aldrich, Saurabh Garg, et al.. (2024). Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer. JAMA Oncology. 11(2). 119–119. 1 indexed citations
4.
Cao, Biwei, Youngchul Kim, Peter Forsyth, et al.. (2024). Factors associated with overall survival in breast cancer patients with leptomeningeal disease (LMD): a single institutional retrospective review. Breast Cancer Research. 26(1). 55–55. 5 indexed citations
5.
Münster, Pamela N., A. Elias, Aixa Soyano, et al.. (2024). LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients. Annals of Oncology. 35. S1220–S1220. 5 indexed citations
6.
Soliman, Hatem, Hyo S. Han, Blaise Mooney, et al.. (2023). Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nature Medicine. 29(2). 450–457. 50 indexed citations
7.
Mills, Matthew N., Aixa Soyano, Yolanda Piña, et al.. (2022). Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease. Journal of Neuro-Oncology. 157(2). 249–269. 10 indexed citations
8.
Barakat, Elie, Anupam Rishi, Jessica M. Frakes, et al.. (2021). Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study. Advances in Radiation Oncology. 7(1). 100838–100838. 7 indexed citations
9.
Mills, Matthew N., Yuki Kawahara, Nicholas Figura, et al.. (2021). The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs. Breast Cancer Research and Treatment. 191(1). 209–217. 8 indexed citations
10.
Mills, Matthew N., Nicholas Figura, Daniel Oliver, et al.. (2021). Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. Journal of Neuro-Oncology. 152(3). 591–601. 8 indexed citations
11.
Kawahara, Yuki, Matthew N. Mills, Nicholas Figura, et al.. (2021). Presentation and management of patients with brain metastases of primary melanoma, non-small cell lung cancer, and breast cancer origin.. Journal of Clinical Oncology. 39(15_suppl). 2033–2033. 1 indexed citations
12.
Soyano, Aixa, et al.. (2019). Adjunctive Use of Circulating Tumor DNA Testing in Detecting Pancreas Cancer Recurrence. Frontiers in Oncology. 9. 46–46. 3 indexed citations
13.
Sokol, Ethan, Lee A. Albacker, Aixa Soyano, et al.. (2019). Abstract 4894: Incidence of high tumor mutation burden (TMB) and PD-L1 positivity in breast cancers and potential response to immune checkpoint inhibitors (ICPIs). Cancer Research. 79(13_Supplement). 4894–4894. 3 indexed citations
14.
Soyano, Aixa, Bhagirathbhai Dholaria, Julian A. Marin‐Acevedo, et al.. (2018). Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. Journal for ImmunoTherapy of Cancer. 6(1). 129–129. 97 indexed citations
15.
Marin‐Acevedo, Julian A., Bhagirathbhai Dholaria, Aixa Soyano, et al.. (2018). Next generation of immune checkpoint therapy in cancer: new developments and challenges. Journal of Hematology & Oncology. 11(1). 39–39. 608 indexed citations breakdown →
16.
Lou, Yanyan, Bhagirathbhai Dholaria, Aixa Soyano, et al.. (2018). Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Medicine. 7(10). 4932–4942. 25 indexed citations
17.
Marin‐Acevedo, Julian A., Aixa Soyano, Bhagirathbhai Dholaria, Keith L. Knutson, & Yanyan Lou. (2018). Cancer immunotherapy beyond immune checkpoint inhibitors. Journal of Hematology & Oncology. 11(1). 8–8. 154 indexed citations
18.
Soyano, Aixa, et al.. (2018). BRCA Mutation and Its Association With Colorectal Cancer. Clinical Colorectal Cancer. 17(4). e647–e650. 19 indexed citations
19.
Soyano, Aixa, Mahwash Kassi, & Pashtoon Murtaza Kasi. (2017). Neuroendocrine Tumor Involving the Epicardium. Case Reports in Oncology. 10(3). 1144–1149. 2 indexed citations
20.
Soyano, Aixa, et al.. (2017). Rifaximin for Pertuzumab-Related GI Toxicities. Frontiers in Oncology. 7. 168–168. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026